Is it safe to stop clopidogrel (Plavix) for one week before surgery?

Stopping Plavix for 1 Week Before Surgery

For most surgeries with major bleeding risk, stopping clopidogrel (Plavix) for 5 days—not 7 days—is the current evidence-based recommendation, though the 7-day window remains acceptable and is still widely referenced in older guidelines. 1, 2

Current Guideline-Based Recommendations

Standard Pre-operative Management

• The American College of Chest Physicians (2022) recommends stopping clopidogrel ≥5 days before surgery with major bleeding risk (the most recent high-quality guideline). 1

• The FDA-approved Plavix label states: "When possible, interrupt therapy with Plavix for five days prior to such surgery" for procedures with major bleeding risk. 2

• Older Canadian Cardiovascular Society guidelines (2011) recommended 7–10 days, which explains why the 7-day window is still commonly practiced, though this has been superseded by the 2022 ACCP recommendation. 3, 4

Critical Exception: Recent Coronary Stents

Never stop clopidogrel within the critical stent-protection window without accepting catastrophic thrombotic risk:

• Bare-metal stent (BMS) placed ≤6 weeks ago: Continue both aspirin AND clopidogrel through surgery (Class I, Level B). 3, 4, 5

• Drug-eluting stent (DES) placed ≤12 months ago: Continue both aspirin AND clopidogrel through surgery (Class I, Level B). 3, 4, 5

• Elective surgery should be deferred until after these critical windows (≥6 weeks for BMS; ≥12 months for DES). 3, 4, 1, 5

CABG-Specific Guidance

• For elective coronary artery bypass grafting, discontinue clopidogrel ≥5 days before surgery (Class I, Level B). 3, 4

• For high ischemic risk AND high bleeding risk patients undergoing CABG, a shorter 3–5 day interruption may be acceptable. 3

Low-Bleeding-Risk Procedures: Continue Clopidogrel

For minor procedures, stopping clopidogrel is unnecessary and increases thrombotic risk without benefit:

• Minor dental procedures (extractions, cleanings, minor oral surgery): Continue clopidogrel (Class IIa, Level A for aspirin continuation; Class IIa, Level C for clopidogrel). 3, 4, 6

• Minor eye or skin procedures: Continue clopidogrel (Class IIa, Level C). 3, 4, 6

• Arthrocentesis: Continue clopidogrel if cardiovascular risk is high (Class IIb, Level C). 3, 4

• Diagnostic tests with low bleeding risk: Continue clopidogrel without interruption. 3, 4

Post-operative Resumption

• Resume clopidogrel within 24 hours after surgery once hemostasis is achieved (the FDA label and ACCP both emphasize restarting "as soon as possible"). 1, 2

• Resume at the usual maintenance dose (75 mg daily) without a loading dose. 7

• Delay resumption beyond 24 hours only if:

  • Inadequate hemostasis at the surgical site 7
  • Ongoing bleeding or significant hematoma requiring continued drainage 7
  • Planned additional surgical interventions 7
  • Post-procedure thrombocytopenia (platelet count <50 × 10⁹/L) 7

Evidence on the 7-Day Window

The research evidence on whether 7 days is "enough" is mixed, but guidelines have moved toward 5 days:

• One retrospective study found no significant difference in reoperation rates between patients stopping clopidogrel >7 days versus <7 days before surgery (5% vs 7.5%, p=NS), though both groups had higher bleeding rates than non-clopidogrel patients. 8

• A prospective randomized trial in general surgery found no difference in bleeding complications between patients stopping clopidogrel 7 days before surgery versus continuing it through surgery, suggesting that for many general surgery procedures, even continuation may be safe. 9

• A hip fracture study found no increased bleeding risk when clopidogrel was stopped for only 3–6 days versus ≥7 days, with similar transfusion requirements and no severe intra-operative bleeding in either group. 10

• However, another retrospective study found that 21.4% of patients taking clopidogrel within 6 days of surgery required transfusion versus 9.5% who stopped ≥7 days, though this difference was not statistically significant (p=0.12). 11

Aspirin Co-therapy

• Continue aspirin throughout the perioperative period for patients on dual antiplatelet therapy, unless bleeding risk is exceptionally high (Class IIa, Level B for high cardiovascular risk patients). 3, 4, 1, 6

• Aspirin should be continued up to the time of surgery for patients requiring CABG (Class I, Level B). 3, 4

Critical Pitfalls to Avoid

• Do not stop clopidogrel in the first 6 weeks after BMS or first 12 months after DES for elective surgery—defer the surgery instead. 3, 4, 5

• Do not stop both aspirin and clopidogrel in stent patients—if clopidogrel must be stopped, continue aspirin. 3, 4, 1

• Do not delay resumption of clopidogrel beyond 24 hours unless there is active bleeding or inadequate hemostasis—discontinuation increases cardiovascular event risk. 1, 2

• Do not stop clopidogrel for low-bleeding-risk procedures (dental work, minor skin/eye procedures)—the thrombotic risk outweighs any bleeding benefit. 3, 4, 6

• Coordinate any decision to hold clopidogrel with the prescribing cardiologist, especially in stent patients or those with recent acute coronary syndrome. 6

Practical Algorithm

Step 1: Identify the indication for clopidogrel

• Recent stent (BMS <6 weeks or DES <12 months)? → Continue clopidogrel through surgery 3, 4, 5
• Acute coronary syndrome within 12 months? → Continue clopidogrel through surgery 5
• Otherwise → Proceed to Step 2

Step 2: Classify surgical bleeding risk

• Low bleeding risk (dental, minor skin/eye, arthrocentesis)? → Continue clopidogrel 3, 4, 6
• Major bleeding risk? → Proceed to Step 3

Step 3: Plan interruption

• Stop clopidogrel 5 days before surgery (current standard) 1, 2
• Continue aspirin if patient is on dual antiplatelet therapy 3, 4, 1
• Resume clopidogrel within 24 hours post-operatively once hemostasis is achieved 1, 2